Sep 26, 2022

Innocoll and DURECT Announce U.S. launch of POSIMIR®

Jul 08, 2022

Innocoll Announces Strategic Investment from Hillhouse Investment

Jul 06, 2022

Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression

Mar 02, 2022

Innocoll Announces Positive Topline Results for XARACOLL® (bupivacaine hydrochloride) Implant in a Phase 3 Study to Support Expanded Use

Feb 25, 2022

Innocoll Announces Co-Promotion Agreement for Hernia Product Portfolio

Feb 22, 2022

Innocoll Announces Successful Completion of Debt Refinancing

Dec 23, 2021

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

Apr 15, 2021

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant

Feb 10, 2021

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

Jan 12, 2021

Louis Pascarella Appointed Chief Executive Officer of Innocoll